$2.57 Billion is the total value of Tekla Capital Management LLC's 187 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ESPR | New | Esperion Therapeutics, Inc. | $13,691,000 | – | 189,287 | +100.0% | 0.53% | – |
| NKTR | New | Nektar Therapeutics | $13,231,000 | – | 124,517 | +100.0% | 0.52% | – |
| MDCO | New | The Medicines Company | $9,170,000 | – | 278,391 | +100.0% | 0.36% | – |
| BPMC | New | Blueprint Medicines Corporation | $6,806,000 | – | 74,221 | +100.0% | 0.26% | – |
| CRSP | New | CRISPR Therapeutics AG | $6,454,000 | – | 141,191 | +100.0% | 0.25% | – |
| FGEN | New | FibroGen, Inc. | $4,819,000 | – | 104,307 | +100.0% | 0.19% | – |
| EDIT | New | Editas Medicine, Inc. | $4,568,000 | – | 137,801 | +100.0% | 0.18% | – |
| BHVN | New | Biohaven Pharmaceutical Holding Company Ltd. | $4,185,000 | – | 162,477 | +100.0% | 0.16% | – |
| ALBO | New | Albireo Pharma, Inc. | $4,071,000 | – | 125,000 | +100.0% | 0.16% | – |
| BDX | New | Becton, Dickinson and Company | $3,739,000 | – | 17,254 | +100.0% | 0.14% | – |
| MASI | New | Masimo Corporation | $3,665,000 | – | 41,666 | +100.0% | 0.14% | – |
| ALDR | New | Alder Biopharmaceuticals, Inc. | $3,555,000 | – | 279,950 | +100.0% | 0.14% | – |
| NTLA | New | Intellia Therapeutics, Inc. | $3,530,000 | – | 167,381 | +100.0% | 0.14% | – |
| RMD | New | ResMed Inc. | $3,330,000 | – | 33,819 | +100.0% | 0.13% | – |
| PTLA | New | Portola Pharmaceuticals, Inc. | $2,939,000 | – | 89,978 | +100.0% | 0.11% | – |
| BAX | New | Baxter International Inc.sponsored adr | $2,599,000 | – | 39,965 | +100.0% | 0.10% | – |
| ARRY | New | Array BioPharma Inc. | $2,547,000 | – | 156,056 | +100.0% | 0.10% | – |
| ABMD | New | ABIOMED, Inc. | $1,896,000 | – | 6,514 | +100.0% | 0.07% | – |
| TLGT | New | Teligent, Inc. | $1,853,000 | – | 551,429 | +100.0% | 0.07% | – |
| STE | New | STERIS plcshares | $1,551,000 | – | 16,612 | +100.0% | 0.06% | – |
| NLNK | New | NewLink Genetics Corporation | $1,486,000 | – | 205,026 | +100.0% | 0.06% | – |
| AKBA | New | Akebia Therapeutics, Inc. | $1,266,000 | – | 132,849 | +100.0% | 0.05% | – |
| HOLX | New | Hologic, Inc. | $730,000 | – | 19,546 | +100.0% | 0.03% | – |
| ARNA | New | Arena Pharmaceuticals, Inc. | $665,000 | – | 16,827 | +100.0% | 0.03% | – |
| PTCT | New | PTC Therapeutics, Inc. | $658,000 | – | 24,299 | +100.0% | 0.03% | – |
| TFX | New | Teleflex Incorporated | $633,000 | – | 2,482 | +100.0% | 0.02% | – |
| VAR | New | Varian Medical Systems, Inc. | $621,000 | – | 5,065 | +100.0% | 0.02% | – |
| FMI | New | Foundation Medicine, Inc. | $500,000 | – | 6,353 | +100.0% | 0.02% | – |
| EIGR | New | Eiger BioPharmaceuticals, Inc. | $452,000 | – | 45,854 | +100.0% | 0.02% | – |
| NCNA | New | NuCana plcsponsored adr | $464,000 | – | 24,536 | +100.0% | 0.02% | – |
| ASND | New | Ascendis Pharma A/Ssponsored adr | $406,000 | – | 6,214 | +100.0% | 0.02% | – |
| MTEM | New | Molecular Templates, Inc. | $423,000 | – | 52,891 | +100.0% | 0.02% | – |
| ADMS | New | Adamas Pharmaceuticals, Inc. | $399,000 | – | 16,699 | +100.0% | 0.02% | – |
| NTUS | New | Natus Medical Incorporated | $381,000 | – | 11,335 | +100.0% | 0.02% | – |
| AGIO | New | Agios Pharmaceuticals, Inc. | $230,000 | – | 2,810 | +100.0% | 0.01% | – |
| JNCE | New | Jounce Therapeutics, Inc. | $226,000 | – | 10,127 | +100.0% | 0.01% | – |
| TBPH | New | Theravance Biopharma, Inc. | $196,000 | – | 8,083 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.